Key Points {#FPar1}
==========

Oral cysteamine is absorbed after taken by adult patients with cystic fibrosis and accumulates in the bronchial secretions.The pharmacokinetics of cysteamine in people with cystic fibrosis are similar to those reported for people with cystinosis.Although seven of the ten patients experienced side effects typical of cysteamine and led to the withdrawal of one of the participants, the majority of participants continued taking cysteamine.

Introduction {#Sec1}
============

Cystic fibrosis (CF) is an autosomal recessively inherited multi-organ disease that affects 70,000--100,000 people globally \[[@CR1]\]. Most CF morbidity and mortality results from chronic suppurative lung disease \[[@CR2]\]. Many of the bacteria infecting the lungs in CF are frequently resistant to antibiotics \[[@CR3]\] and grow in biofilms, further reducing antibiotic sensitivity \[[@CR4]\]. These issues have led to calls for new antibiotic strategies targeting the biofilm and to increase the effectiveness of currently available antibiotics \[[@CR5], [@CR6]\].

We have previously described the in vitro antimicrobial, anti-biofilm and mucoactive properties of the aminothiol cysteamine as a monotherapy and synergy with CF guideline recommended antibiotics \[[@CR7]--[@CR9]\]. Overall these characteristics suggest that cysteamine could be beneficial in managing CF and warrants further investigation. Although cysteamine has been used to treat nephropathic cystinosis for several decades \[[@CR7]\] and its pharmacokinetic and clinical profiles are established for cystinosis \[[@CR7], [@CR10]--[@CR12]\], there are no such data for cysteamine in CF. In patients with cystinosis, absorption of oral cysteamine may be decreased when taken with food \[[@CR13]\], there is a 40 % first-pass effect, cysteamine circulates bound to plasma proteins, and is metabolised to taurine and excreted in the urine and bile; cysteamine is also excreted in the urine as inorganic sulphate and taurine \[[@CR7], [@CR14]\]. Given the pancreatic and intestinal manifestations of CF and the increased drug metabolism/clearance reported \[[@CR15]\] in CF it is not possible to extrapolate the pharmacokinetics of cysteamine in cystinosis to CF. Critically it is not known in CF whether orally administered cysteamine enters infected airways.

We report here a single-arm, phase 1/2a open label study conducted to confirm in people with CF that oral cysteamine is absorbed, to characterise the pharmacokinetic profile of cysteamine, to ascertain whether cysteamine enters bronchial secretions and to explore tolerability.

Method {#Sec2}
======

This was a single-centre, single-group, open-lable trial of administering oral cysteamine to patients with CF. Figure [1](#Fig1){ref-type="fig"} depicts the study design.Fig. 1Study schedule. *od* once a day, *bd* twice a day, *tds* three times a day, *qds* four times a day

Participants {#Sec3}
------------

Patients attending the adult CF clinic at Aberdeen Royal Infirmary, Aberdeen, UK were invited to participate. The inclusion criteria were: CF lung disease, aged ≥18 years, weight \>50 kg, clinically stable for \>4 weeks, and females of child-bearing potential using a reliable form of contraception. The exclusion criteria were: hypersensitivity to cysteamine, excipients or penicillamine, transplant recipient, pregnancy, planned pregnancy, and breast feeding. The trial was co-sponsored by the University of Aberdeen and NHS Grampian, approved by Scotland-A Research Ethics Committee (14/SS/056), the Medicines and Healthcare products Regulatory Agency (EudraCT 2014-000284-40, CTA 21583/0220/001-0001) and registered with <http://www.clinicaltrials.gov> (NCT02212431). Participants provided written informed consent.

Intervention {#Sec4}
------------

Oral cysteamine bitartrate (Cystagon^®^, Orphan Europe, Henley-upon-Thames, UK) was administered at the dose licensed for cystinosis, i.e. 450 mg four times a day (qds). Participants were commenced on 450 mg once a day, with the dose being increased at weekly intervals to 450 mg twice daily (bd), 450 mg three times a day (tds) and 450 mg, which was administered for 2 weeks (Fig. [1](#Fig1){ref-type="fig"}). As recommended, participants took cysteamine just after/with food \[[@CR16]\].

Follow-Up and Data Collection {#Sec5}
-----------------------------

Participants were assessed at face-to-face visits at recruitment/baseline, and 1, 2, 3, 5 and 6 weeks (Fig. [1](#Fig1){ref-type="fig"}). The recruitment/baseline assessment was conducted in an in-patient facility, all other assessments were conducted in an out-patient facility. At each assessment, blood was obtained for routine clinical haematology and biochemistry. Adverse reactions (ARs) and serious adverse events (SAEs) were ascertained at the 1-, 2-, 3-, 5- and 6-week visits \[[@CR17]\].

### Plasma and Sputum Samples {#Sec6}

At recruitment/assessment blood samples were taken prior to and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10 and 24 h after the first 450-mg cysteamine dose that was administered by a CF nurse specialist. Blood (5 ml) was collected into chilled sodium heparin tubes, stored on ice until centrifuged at 2000*g*, 4 °C for 10 min, and the plasma stored at −70 °C within 1 h of collection. Further blood samples were taken 3 h after the last dose of cysteamine at the 1-, 2-, 3- and 5-week visits. After a planned review of the pharmacokinetic metrics of the first four participants, the 24-h sample after the first dose was made optional because plasma cysteamine was below the lower level of quantification. In addition, the timing of the blood sampling was changed to 8 h after last dosing for the 1-, 2- and 3-week assessments and after 6 h for the 5-week assessment. These revisions were agreed by the Trial Steering Committee. A spontaneously expectorated sample of sputum (\~1 ml) was collected at the 5-week assessment immediately prior to blood sampling and stored at −70 °C within an hour of collection.

### Quantification of Cysteamine {#Sec7}

Plasma and sputum cysteamine was quantified using protein precipitation and derivatisation followed by liquid chromatography with tandem mass spectrometric detection (LC-MS/MS) \[[@CR18]--[@CR20]\] by Covance Laboratories Ltd, Harrogate, UK. The validated method has a calibration range of 0.020--5.000 mg/l. The analytical work was conducted in accordance with: UK Statutory Instrument 2004 No. 1031: The Medicines for Human Clinical Use (Clinical Trials) Regulations 2004, Statutory Instrument 2004 No.994 and Guidelines on Good Clinical Practice: ICH E6: Good Clinical Practice CPMP/ICH/135/95 (July 1996).

### Statistical Considerations {#Sec8}

Primary outcomes were single-dose pharmacokinetic parameters. Secondary outcomes were sputum cysteamine concentration and tolerability. With 12 subjects the study had 80 % power with α = 0.05 to detect a ≥1 SD difference in the mean maximal plasma concentration (*C*~max~) after first dose of cysteamine between cystinosis \[[@CR10]\] and CF patients.

Pharmacokinetic parameters were identified using standard non-compartmental analysis from the single-dose cysteamine concentration against time profiles. *C*~max~ was the greatest measured level and *T*~max~ was the time corresponding to *C*~max~. The elimination rate constant (*k*) was obtained by linear regression of the natural logarithm cysteamine concentration against time from the terminal portion of each profile (i.e. all concentrations after the peak concentration) and the half-life (*t*~½~) was the natural logarithm of two divided by the elimination rate constant. The area under the curve between time *t* = 0 and the last sample (Cfin−the final concentration) was calculated using the trapezoidal rule (AUC~0--Cfin~). The area under the curve (AUC) was the AUC~0--Cfin~ plus the residual area (the final measured concentration divided by the elimination rate constant). The residual area ranged from 4.1 to 13.4 % of the AUC for all participants. Bioavailability (*F*) of cysteamine tablets was not calculated, hence clearance (CL) and volume of distribution (*V*~d~) are reported as the respective parameters divided by *F* (CL/*F* and *V*~d~/*F*, respectively). CL/*F* was obtained by dividing the dose by the AUC and then dividing this value by the elimination rate constant provided *V*~d~/*F*. SPSS, v23.0. (Armonk, NY, USA) was used for data analyses.

Results {#Sec9}
=======

Of the 65 patients attending the CF clinic, 32 were eligible and invited to participate. Ten people participated between September 2014 and February 2015, 22 declined to participate. Two participants discontinued the intervention. Figure [2](#Fig2){ref-type="fig"} outlines flow through the trial. The clinical characteristics of the participants are presented in Table [1](#Tab1){ref-type="table"}.Fig. 2CONSORT flow diagramTable 1Baseline clinical characteristics of participating patientsClinical characteristicValueAge, years, median (interquartile range)21.5 (19.8--31.8)Female, *n* (%)6 (60 %)CF genotype: Phe 508del/Phe 508del, *n* (%)8 (80 %)CF genotype: Phe 508del/--2 (20 %)Body mass index, kg/m^2^, mean (95 % confidence interval)22.1 (20.3--23.9)Forced expiratory volume in first second (FEV~1~) % predicted, median (interquartile range)32 % (26--49)Concomitant medication, *n* (%) Pancreatic enzyme replacement9 (90 %) Azithromycin8 (80 %) Inhaled antibiotic4 (40 %) Nebulised recombinant DNAse3 (30 %) Nebulised 4 % saline1 (10 %) Ivacaftor1 (10 %)Sputum culture, *n* (%) *Staphylococcus aureus*3 (30 %) *Pseudomonas aeruginosa*6 (60 %) *Stenotrophomonas maltophilia*2 (20 %)

Plasma Cysteamine {#Sec10}
-----------------

Serial plasma cysteamine concentrations after the first 450-mg cysteamine dose were quantified in nine participants, venous access issues prevented measurement in one participant. A median (interquartile range, IQR) of 9 (7--10) time points were used to calculate half-life. Plasma cysteamine concentrations and derived pharmacokinetic parameters are presented in Fig. [3](#Fig3){ref-type="fig"} and Table [2](#Tab2){ref-type="table"}. Following 450-mg once a day (*n* = 8), twice a day (*n* = 9), three times a day (*n* = 8) and four times a day (*n* = 8) dosing the mean (SD) plasma cysteamine concentrations were 0.47 (0.26), 0.60 (0.34), 0.85 (0.73) and 0.47 (0.34) mg/l, respectively. Four of the eight patients with measured concentrations on four times a day dosing had lower concentrations than three times a day dosing although their pill counts suggested good adherence.Fig. 3Presentation of data on mean (SD) plasma cysteamine concentrations in the first 24 h after an oral dose of 450 mg (*n* = 9). Data points for t0--10 h are mean (SD) of *n* = 9 and for *t* = 24 h, mean (SD) of *n* = 7Table 2Plasma pharmacokinetic parameters after a single dose of 450 mg cysteamineParameterValue^a^*C* ~max~ (mg/l)2.86 (1.95)*T* ~max~ (min)72 (42)*t* ~½~ (min)222 (102)AUC~0--∞~ (mg·min/l)9.62 (2.02)CL/F (l/min)1.50 (0.51)*V* ~d~/*F* (l)427 (129)*V* ~d~/*F* (l/kg^b^)7.1 (2.1)*C* ~*max*~ maximum concentration, *T* ~*max*~ time corresponding to *C* ~max~, *t* ~*½*~ half-life, *CL/F* clearance, *V* ~*d*~ */F* volume of distribution^a^Values expressed as mean (SD)^b^Actual body weight

Sputum Cysteamine {#Sec11}
-----------------

Six participants were able to expectorate sputum samples immediately before blood sampling at the 5-week assessment. Cysteamine was detected in all of these six sputum samples, median (IQR) sputum cysteamine concentration was 0.84 (0.41--2.10) mg/l. The median (IQR) ratio of sputum to plasma cysteamine concentration was 4.2 (0.98--8.84).

Tolerability {#Sec12}
------------

Adherence as determined by pill counting appeared to be good, with median (IQR) adherence for the once, twice, three times and four times daily dosing being 100 % (100--100), 100 % (93--100), 98 % (95--100) and 98 % (79--100), respectively.

Two participants discontinued the intervention: one during the first week because of halitosis (an adverse reaction \[AR\] related to cysteamine); the second during week three because of recurrence of haemoptysis that continued after ceasing medication (an AR unrelated to cysteamine). There were two SAEs: one participant was hospitalised twice with infective exacerbations of CF lung disease. These SAEs were deemed unrelated to cysteamine. There were no deaths. Gastrointestinal ARs (anorexia, nausea, vomiting) were reported by four participants, for three this was either short lived (2 days), very mild or resolved with an increased dose of proton pump inhibitor; for one participant symptoms persisted throughout the trial. Neurological ARs (lethargy, somnolence, forgetfulness) were reported by three participants. One participant reported a transient rash after commencing cysteamine (a possible AR). Seven participants reported at least one AR. Two participants reported AEs judged unrelated to cysteamine. One participant reported no AE/ARs.

Discussion {#Sec13}
==========

We have shown that in adults with CF, oral cysteamine is absorbed and enters the bronchial secretions with a higher concentration than plasma values. Although ARs were common, most participants continued the intervention.

Most of the plasma pharmacokinetic parameters reported here in patients with CF are similar to those reported in cystinosis \[[@CR10]--[@CR12]\]. In patients with cystinosis, Belldina reported a two-compartment model with *C*~max~ 2.7 mg/l and *T*~max~ 84 min \[[@CR11]\], Langman reported *C*~max~ 2.73 mg/l, *T*~max~ 72 min and clearance 1.33 l/min \[[@CR10]\]. In our CF patients volume of distribution and *t*~½~ were greater than those reported after similar single dosing in people with cystinosis (*V*~d~/*F* = 180 L, SD 112, *t*~½~ = 90 min, SD 23) \[[@CR10]\], suggesting that whilst cysteamine absorption is similar in cystinosis and CF, distribution and elimination differ. The volume of distribution of cysteamine in people with CF exceeds extracellular fluid volume, being similar to that reported for aminoglycosides in CF. For aminoglycosides this has been attributed to the compromised nutritional status of patients with CF \[[@CR15]\]. The between-subject variability of pharmacokinetic parameters as evidenced by greater standard deviation values we report in CF patients is greater than that reported for cystinosis \[[@CR10]--[@CR12]\]. This may be a consequence of cysteamine being taken with food, a factor known to cause wide variation in cysteamine *T*~max~ and *C*~max~ \[[@CR13]\]. Given the importance of maintaining nutritional status in CF, it was not considered appropriate for subjects to fast. Consideration of the physical properties of cysteamine (acid dissociation constant, p*K*a = 10.4, partition coefficient, log*P* = 0.01) \[[@CR21]\] predicts that cysteamine concentration in the acidic bronchial secretions of CF (pH 6.0--6.9) \[[@CR22]\] should be higher than in the systemic circulation, which is consistent with our findings. A study published whilst our study was being conducted reported that oral cysteamine was absorbed by CF patients \[[@CR23]\]. Although similar in size to our study (*n* = 10), this study differed somewhat: participants were younger, had milder lung disease, were all Phe508del homozygous and plasma cysteamine was quantified at baseline, 2 and 6 h for nine subjects and hourly for 6 h for one subject.

The side effects of cysteamine are well documented for cystinosis and consistent with what we observed in our CF patients, with seven participants (70 %) reporting ARs. Gastrointestinal ARs were most common and probably similar incidence to those reported for cystinosis. More participants reported neurological ARs (lethargy, somnolence, forgetfulness) than would be expected from the cystinosis data. Although pill counts indicated good adherence, the lower plasma levels after qds dosing compared to tds dosing suggested greater adherence with tds dosing. Anecdotally, participants spontaneously volunteered that they found qds dosing very difficult to incorporate into their daily routine. It is possible that for the qds dosing some of the capsules taken from the bottles were not taken. In patients with cystinosis, adherence is also poor in up to 70--80 % of patients because of qds dosing and side effects \[[@CR24]--[@CR26]\].

The strengths of the current study are that the pharmacokinetic characteristics of cysteamine were established by serial measurements of plasma cysteamine after single dosing. When compared with UK CF Registry data the patients participating in the current study had a greater predominance of Phe508del homozygotes, lower lung function, but similar BMI, *Pseudomonas* infection and treatment modalities \[[@CR27]\]. Quantification of sputum cysteamine was a further strength. Although sufficient to characterise pharmacokinetic parameters the small number of participants is a weakness. Our aim was to recruit 12 patients; however, ten volunteered, but this was in line with pre-study expectations given the small clinic size and the intensive nature of the study.

Conclusion {#Sec013}
==========

In conclusion, we have shown that in people with CF, oral cysteamine is absorbed and preferentially accumulates in sputum. However, randomised controlled trials are required to establish whether and under what circumstances cysteamine could be used in the management of CF.
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